{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T19:15:21Z","timestamp":1766171721328,"version":"3.48.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Munich Medical & Clinician Scientist Program, LMU Munich,","award":["CS 051"],"award-info":[{"award-number":["CS 051"]}]},{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Uveal effusion syndrome (UES) is characterized by exudative detachments of choroid, ciliary body and retina. Like central serous chorioretinopathy (CSCR) it is associated with scleral thickening inhibiting fluid outflow. Recently, decreased levels of Lipocalin-2 (LCN2) and Pentraxin-3 (PTX3) were found in CSCR. The aim of this study was to measure these parameters in patients with UES to evaluate a possible pachychoroid continuum with UES as the maximum form.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A randomized prospective case\u2013control study was performed at the Ludwig Maximilians University, Department of Ophthalmology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In patients with UES and in an age- BMI- and sex-matched control group, subfoveal choroidal thickness (SFCT) on optical coherence tomography imaging and the serum levels of PTX3 and LCN2 were measured.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      12 patients were included in each group. SFCT was significantly thicker in the UES group compared to the normal controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0003). LCN2 and PTX3 values tended to be lower in patients with UES (LCN2: 65.74\u2009\u00b1\u200933.81 (33.7\u2009\u2212\u2009165.4) ng\/ml vs. 108.8\u2009\u00b1\u200967.1 (40.8\u2009\u2212\u2009261.9,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.133) ng\/ml PTX3: 0.82\u2009\u00b1\u20090.52 (0.13\u2009\u2212\u20092.1) ng\/ml vs. 1.23\u2009\u00b1\u20090.77 (0.3\u2009\u2212\u20091.86,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.260) ng\/ml.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Lipocalin-2 and Pentraxin-3 values, which are known to be induced by glucocorticoids, tend to be lower in patients with UES. The results suggest an impairment in the glucocorticoid receptor pathway and underline the hypothesis of a common pathophysiological pathway of CSCR and UES.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10792-025-03835-5","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T04:18:20Z","timestamp":1762316300000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pentraxin-3 and Lipocalin-2 are decreased in patients with uveal effusion syndrome"],"prefix":"10.1007","volume":"45","author":[{"given":"Caroline","family":"Havertz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedikt","family":"Schworm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Siedlecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Wilfert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Northoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siegfried G.","family":"Priglinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonie F.","family":"Keidel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"issue":"2","key":"3835_CR1","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1016\/j.jcjo.2019.08.002","volume":"55","author":"S Jin","year":"2020","unstructured":"Jin S, Francisconi CLM, Wong DT (2020) Pachychoroid findings in a case of uveal effusion syndrome. Can J Ophthalmol 55(2):e74\u2013e76","journal-title":"Can J Ophthalmol"},{"issue":"3","key":"3835_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0161-6420(99)00141-4","volume":"107","author":"M Uyama","year":"2000","unstructured":"Uyama M et al (2000) Uveal effusion syndrome: clinical features, surgical treatment, histologic examination of the sclera, and pathophysiology. Ophthalmology 107(3):441\u2013449","journal-title":"Ophthalmology"},{"key":"3835_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12093102","author":"LF Keidel","year":"2023","unstructured":"Keidel LF et al (2023) Scleral thickness as a risk factor for central serous chorioretinopathy and pachychoroid neovasculopathy. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12093102","journal-title":"J Clin Med"},{"issue":"1","key":"3835_CR4","doi-asserted-by":"publisher","first-page":"19505","DOI":"10.1038\/s41598-020-75789-w","volume":"10","author":"H Matsumoto","year":"2020","unstructured":"Matsumoto H et al (2020) Quantitative measures of vortex veins in the posterior pole in eyes with pachychoroid spectrum diseases. Sci Rep 10(1):19505","journal-title":"Sci Rep"},{"issue":"11","key":"3835_CR5","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1001\/archopht.1980.01020040839008","volume":"98","author":"RJ Brockhurst","year":"1980","unstructured":"Brockhurst RJ (1980) Vortex vein decompression for nanophthalmic uveal effusion. Arch Ophthalmol 98(11):1987\u20131990","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"3835_CR6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.survophthal.2009.05.003","volume":"55","author":"M Elagouz","year":"2010","unstructured":"Elagouz M, Stanescu-Segall D, Jackson TL (2010) Uveal effusion syndrome. Surv Ophthalmol 55(2):134\u2013145","journal-title":"Surv Ophthalmol"},{"key":"3835_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1001\/archopht.1963.00960050191010","volume":"70","author":"CL Schepens","year":"1963","unstructured":"Schepens CL, Brockhurst RJ (1963) Uveal effusion. 1. Clinical picture. Arch Ophthalmol 70:189\u2013201","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"3835_CR8","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.oret.2019.08.002","volume":"3","author":"J Siedlecki","year":"2019","unstructured":"Siedlecki J, Schworm B, Priglinger SG (2019) The pachychoroid disease spectrum-and the need for a uniform classification system. Ophthalmol Retina 3(12):1013\u20131015","journal-title":"Ophthalmol Retina"},{"issue":"4","key":"3835_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s10384-020-00740-5","volume":"64","author":"Y Yanagi","year":"2020","unstructured":"Yanagi Y (2020) Pachychoroid disease: a new perspective on exudative maculopathy. Jpn J Ophthalmol 64(4):323\u2013337","journal-title":"Jpn J Ophthalmol"},{"issue":"3","key":"3835_CR10","doi-asserted-by":"publisher","first-page":"100278","DOI":"10.1016\/j.xops.2023.100278","volume":"3","author":"E Bousquet","year":"2023","unstructured":"Bousquet E et al (2023) High levels of C-reactive protein with low levels of pentraxin 3 as biomarkers for central serous chorioretinopathy. Ophthalmol Sci 3(3):100278","journal-title":"Ophthalmol Sci"},{"issue":"1","key":"3835_CR11","doi-asserted-by":"publisher","first-page":"20175","DOI":"10.1038\/s41598-020-77202-y","volume":"10","author":"A Matet","year":"2020","unstructured":"Matet A et al (2020) Lipocalin 2 as a potential systemic biomarker for central serous chorioretinopathy. Sci Rep 10(1):20175","journal-title":"Sci Rep"},{"issue":"44","key":"3835_CR12","doi-asserted-by":"publisher","first-page":"29983","DOI":"10.1074\/jbc.M805631200","volume":"283","author":"A Doni","year":"2008","unstructured":"Doni A et al (2008) Cell-specific regulation of PTX3 by glucocorticoid hormones in hematopoietic and nonhematopoietic cells. J Biol Chem 283(44):29983\u201329992","journal-title":"J Biol Chem"},{"issue":"9","key":"3835_CR13","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.4049\/jimmunol.1701573","volume":"200","author":"T Parmar","year":"2018","unstructured":"Parmar T et al (2018) Lipocalin 2 plays an important role in regulating inflammation in retinal degeneration. J Immunol 200(9):3128\u20133141","journal-title":"J Immunol"},{"key":"3835_CR14","first-page":"303","volume":"19","author":"JM Woo","year":"2013","unstructured":"Woo JM et al (2013) Human retinal pigment epithelial cells express the long pentraxin PTX3. Mol Vis 19:303\u2013310","journal-title":"Mol Vis"},{"key":"3835_CR15","doi-asserted-by":"publisher","first-page":"101311","DOI":"10.1016\/j.ajoc.2022.101311","volume":"25","author":"T Tran","year":"2022","unstructured":"Tran T et al (2022) Choroidal effusion as a manifestation of central serous chorioretinopathy: a case report. Am J Ophthalmol Case Rep 25:101311","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"5","key":"3835_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/jb\/mvu086","volume":"157","author":"S Yamazaki","year":"2015","unstructured":"Yamazaki S, Akira S, Sumimoto H (2015) Glucocorticoid augments lipopolysaccharide-induced activation of the I\u03baB\u03b6-dependent genes encoding the anti-microbial glycoproteins lipocalin 2 and pentraxin 3. J Biochem 157(5):399\u2013410","journal-title":"J Biochem"},{"key":"3835_CR17","doi-asserted-by":"publisher","first-page":"785444","DOI":"10.3389\/fmed.2022.785444","volume":"9","author":"N Zhou","year":"2022","unstructured":"Zhou N et al (2022) Uveal effusion syndrome: clinical characteristics, outcome of surgical treatment, and histopathological examination of the sclera. Front Med 9:785444","journal-title":"Front Med"},{"issue":"2","key":"3835_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ajo.2005.02.014","volume":"140","author":"A Lam","year":"2005","unstructured":"Lam A, Sambursky RP, Maguire JI (2005) Measurement of scleral thickness in uveal effusion syndrome. Am J Ophthalmol 140(2):329\u2013331","journal-title":"Am J Ophthalmol"},{"issue":"Pt 2","key":"3835_CR19","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/eye.1990.48","volume":"4","author":"JV Forrester","year":"1990","unstructured":"Forrester JV et al (1990) The uveal effusion syndrome and trans-scleral flow. Eye (Lond) 4(Pt 2):354\u2013365","journal-title":"Eye (Lond)"},{"key":"3835_CR20","first-page":"246","volume":"81","author":"JD Gass","year":"1983","unstructured":"Gass JD (1983) Uveal effusion syndrome: a new hypothesis concerning pathogenesis and technique of surgical treatment. Trans Am Ophthalmol Soc 81:246\u2013260","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"5","key":"3835_CR21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1001\/archopht.1973.01000050401015","volume":"90","author":"RJ Brockhurst","year":"1973","unstructured":"Brockhurst RJ, Lam KW (1973) Uveal effusion. Part II. Report of a case with analysis of subretinal fluid. Arch Ophthalmol 90(5):399\u2013401","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"3835_CR22","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1097\/IAE.0000000000003376","volume":"42","author":"N Terao","year":"2022","unstructured":"Terao N et al (2022) Ciliochoroidal effusion in central serous chorioretinopathy. Retina 42(4):730\u2013737","journal-title":"Retina"},{"issue":"1","key":"3835_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12886-022-02316-y","volume":"22","author":"H Onoe","year":"2022","unstructured":"Onoe H et al (2022) Bilateral pachychoroid disease with type 3 uveal effusion syndrome in one eye and central serous chorioretinopathy in contralateral eye: a case report. BMC Ophthalmol 22(1):91","journal-title":"BMC Ophthalmol"},{"issue":"9","key":"3835_CR24","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1097\/IAE.0b013e3181e7976b","volume":"30","author":"KB Freund","year":"2010","unstructured":"Freund KB, Zweifel SA, Engelbert M (2010) Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina 30(9):1333\u20131349","journal-title":"Retina"},{"key":"3835_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20236028","author":"N Hwang","year":"2019","unstructured":"Hwang N et al (2019) Oxidative stress-induced pentraxin 3 expression human retinal pigment epithelial cells is involved in the pathogenesis of age-related macular degeneration. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20236028","journal-title":"Int J Mol Sci"},{"key":"3835_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1146\/annurev-immunol-030409-101305","volume":"28","author":"B Bottazzi","year":"2010","unstructured":"Bottazzi B et al (2010) An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol 28:157\u2013183","journal-title":"Annu Rev Immunol"},{"key":"3835_CR27","doi-asserted-by":"publisher","first-page":"811344","DOI":"10.3389\/fphar.2021.811344","volume":"12","author":"M Stravalaci","year":"2021","unstructured":"Stravalaci M et al (2021) The long pentraxin PTX3 as a new biomarker and pharmacological target in age-related macular degeneration and diabetic retinopathy. Front Pharmacol 12:811344","journal-title":"Front Pharmacol"},{"issue":"5","key":"3835_CR28","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1177\/1120672120969369","volume":"31","author":"R Sharma","year":"2021","unstructured":"Sharma R, Foot B, Jackson TL (2021) A prospective, population-based, surveillance (BOSU) study of uveal effusion syndrome in the UK. Eur J Ophthalmol 31(5):2451\u20132456","journal-title":"Eur J Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03835-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03835-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03835-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T19:02:10Z","timestamp":1766170930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03835-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3835"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03835-5","relation":{},"ISSN":["1573-2630"],"issn-type":[{"type":"electronic","value":"1573-2630"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article. Caroline Havertz has no financial disclosure to declare. Benedikt Schworm has received previous speaker fees of Novartis Pharma. Jacob Siedlecki is part of the advisory board and got honoraria of Novaris Pharma, Abbvie\/Pharm-Allergan, Roche, Apellis, Sandoz\/Hexal, he is part of the advisory board of Bayer. Wolfgang Wilfert has no financial disclosure to declare. Bernd Northoff has no financial disclosure to declare. Siegfried Priglinger is part of the advisory board and received previous honoraria of Novartis Pharma, Pharm Allergan, Zeiss, Bayer, Bausch and Lomb, Roche, AbbVie, he is a Consulant of BVI Medical, Bausch and Lomb, Roche and AbbVie. Leonie Keidel received previous speaker fees and\/or travel expenses from Novartis Pharma, Recordati Rare Diseases Inc., CHIESI, Roche Diagnostics, DORC Holding BV and Santen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was classified as ethically and legally unobjectionable by the ethics committee of the LMU Munich (Identifier: 24-0241). Each patient was informed about participation in the study and gave written consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided written consent prior to any study-related procedure. Informed consent was obtained from all subjects involved in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"461"}}